Hiv Aids Treatment Articles & Analysis
14 news found
Hao Yang, President of China Association for STD and AIDS Prevention and Treatment; Mrs. Wang Xinlun, Vice President and Secretary-General of China Association for STD and AIDS Prevention and Treatment, industry experts and representatives of partner companies and institutions attended the ceremony. Since China initiated ...
As the leading expert in computer-aided drug discovery, BOC Sciences has developed compound docking technologies to facilitate the discovery of novel ligands for over 30 targets. ...
Currently, there are 9,900 people living with HIV (PLHIV) in Azerbaijan and 57% are receiving antiretroviral treatment (ART). ...
Continued the recruitment for two Phase 2 clinical trials of BIT225 for treatment of HIV-1 infection at sites in Australia and Thailand. Continued the design, synthesis and testing of new compounds under its HIV-1 program, with the aim of identifying a next generation lead anti-HIV-1 drug. ...
Multiple controlled clinical trials and accumulated real-world data show that Aikening® has high efficacy and safety, with minimal drug interactions with commonly used drugs amongst HIV patients and high resistance barriers. We are very happy to partner with R-Pharm to bring Chinese innovative drug to Russian AIDS patients". ...
The TALENT study (TALENT) findings, which were presented at the 11th International AIDS Society (IAS) Conference on HIV Science, showed that a two-drug regimen was as effective and safe as multi-drug therapies TALENT is the world's first phase III clinical trial of the new long-acting HIV-1 fusion inhibitor, Aikening® (generic name: ...
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering GPCR-targeted therapeutics, today announced the results of their Phase 1 study of OB-002H which is an investigational candidate microbicide for HIV prevention. The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic profile of OB-002H ...
Orion Biotechnology Canada Ltd., a clinical stage pharmaceutical company focused on precision engineering small protein therapeutics, today announced successful completion of participant follow-up in their Phase 1 study of OB-002H which is an investigational candidate microbicide. The Phase 1 study was a first-in-man trial designed to evaluate the safety, acceptability, and pharmacokinetic ...
"One of our Foundation's major goals is to find a disease-modifying therapy for HIV/AIDS," said Ken Rapkin, Program Officer of Campbell. "The challenges associated with the delivery of HIV drugs through the BBB represent a critical unmet need in the field of AIDS research. This project’s success bodes well for the future of ...
Delayed test results often mean HIV patients in Mozambique fail to get timely treatment, but new technology is reducing the need to send tests to far away laboratories, and speeding up test results and HIV treatment. ...
The second phase initiatives include: the prevention of HIV, the critical need to treat people living with HIV for tuberculosis (TB) and the sustainability of the program to allow Botswana to successfully address HIV/AIDS within its own borders. ...
People Encouraging People of Baltimore was awarded a $150,000 grant to support Project OPEN, a mobile treatment service offered to people at high risk of contracting HIV/AIDS or who have lost coverage for their HIV/AIDS treatment. ...
ViiV Healthcare is seeking letters of interest (LOIs) to support programs specifically focused on reducing disparities in HIV/AIDS linkages to care and treatment among African American and Latinos in Alabama, Georgia, Louisiana and Mississippi. ...
Today, ViiV Healthcare and the Elizabeth Glaser Pediatric AIDS Foundation announced a new partnership that will expedite access to lifesaving HIV care and treatment and help children live longer, healthier, and more productive lives. ...